These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3332 related articles for article (PubMed ID: 7638983)

  • 1. Megestrol melanoma study.
    Nathanson L; Garrison M
    World J Surg; 1995; 19(3):337-42. PubMed ID: 7638983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemohormone therapy of metastatic melanoma with megestrol acetate plus dacarbazine, carmustine, and cisplatin.
    Nathanson L; Meelu MA; Losada R
    Cancer; 1994 Jan; 73(1):98-102. PubMed ID: 8275444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.
    Rusthoven JJ; Quirt IC; Iscoe NA; McCulloch PB; James KW; Lohmann RC; Jensen J; Burdette-Radoux S; Bodurtha AJ; Silver HK; Verma S; Armitage GR; Zee B; Bennett K
    J Clin Oncol; 1996 Jul; 14(7):2083-90. PubMed ID: 8683240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11.
    Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C
    Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma.
    Chapman PB; Einhorn LH; Meyers ML; Saxman S; Destro AN; Panageas KS; Begg CB; Agarwala SS; Schuchter LM; Ernstoff MS; Houghton AN; Kirkwood JM
    J Clin Oncol; 1999 Sep; 17(9):2745-51. PubMed ID: 10561349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I/II study of a cisplatin-taxol-dacarbazine regimen in metastatic melanoma.
    Papadopoulos NE; Bedikian A; Ring S; Kim KB; Hwu WJ; Gerber DL; Homsi J; Hwu P
    Am J Clin Oncol; 2009 Oct; 32(5):509-14. PubMed ID: 19506454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Franzke A; Körfer A; Volkenandt M; Duensing S; Schomburg A; Chaitchik S; Poliwoda H
    Eur J Cancer; 1995 Jun; 31A(6):876-81. PubMed ID: 7646914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.
    Steffens TA; Bajorin DF; Chapman PB; Lovett DR; Cody-Johnson BV; Templeton MA; Heelan RT; Wong GY; Portlock CS; Oettgen HF
    Cancer; 1991 Sep; 68(6):1230-7. PubMed ID: 1873774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential chemoimmunotherapy for metastatic melanoma.
    Richards JM
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):91-5. PubMed ID: 1948135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study.
    Margolin KA; Liu PY; Flaherty LE; Sosman JA; Walker MJ; Smith JW; Fletcher WS; Weiss GR; Unger JM; Sondak VK
    J Clin Oncol; 1998 Feb; 16(2):664-9. PubMed ID: 9469356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy (dacarbazine, carmustine, cisplastin, and tamoxifen) in advanced melanoma.
    Tan EH; Ang PT
    Singapore Med J; 1996 Apr; 37(2):165-7. PubMed ID: 8942255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma.
    Richard MA; Grob JJ; Zarrour H; Bassères N; Bizzari JP; Gérard B; Bonerandi JJ
    Melanoma Res; 1998 Apr; 8(2):170-4. PubMed ID: 9610872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
    Jelić S; Babovic N; Kovcin V; Milicevic N; Milanovic N; Popov I; Radosavljevic D
    Melanoma Res; 2002 Feb; 12(1):91-8. PubMed ID: 11828263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of stage IV malignant melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study.
    Saba HI; Cruse CW; Wells KE; Klein CJ; Reintgen DS
    Ann Plast Surg; 1992 Jan; 28(1):65-9. PubMed ID: 1642409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma.
    Creagan ET; Suman VJ; Dalton RJ; Pitot HC; Long HJ; Veeder MH; Vukov AM; Rowland KM; Krook JE; Michalak JC
    J Clin Oncol; 1999 Jun; 17(6):1884-90. PubMed ID: 10561229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.
    Buzaid AC; Murren JR; Durivage HJ
    Cancer; 1991 Sep; 68(6):1238-41. PubMed ID: 1873775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemotherapy with carmustine, cisplatin, dacarbazine, tamoxifen and low-dose interleukin-2 for patients with metastatic malignant melanoma.
    Su PJ; Chen JS; Liaw CC; Chang HK; Wang HM; Yang TS; Lin YC; Liau CT; Yang HY; Yeh KY; Ho MM; Chang NJ; Wang CH; Chang JW
    Chang Gung Med J; 2011; 34(5):478-86. PubMed ID: 22035892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoimmunohormonal therapy with carmustine, dacarbazine, cisplatin, tamoxifen, and interferon for metastatic melanoma: a prospective phase II study.
    Stein ME; Bernstein Z; Tsalic M; Drumea K; Steiner M; Sklar Z; Haim N
    Am J Clin Oncol; 2002 Oct; 25(5):460-3. PubMed ID: 12393984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 167.